One group of AML patients that has an enhanced risk of hyperleukocytosis, are patients with a mutation in the juxtamembrane domain, called internal tandem duplication, of Fms-Related Tyrosine Kinase 3 (FLT3-ITD) (7). Here, FLT3 is linked to acute myeloid leukemia.